Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Rapport Therapeutics, Inc. ( (RAPP) ) is now available.
On September 8, 2025, Rapport Therapeutics announced positive topline results from its Phase 2a clinical trial of RAP-219 in patients with drug-resistant focal onset seizures. The trial demonstrated statistically significant reductions in long episodes and clinical seizures, with 85.2% of patients achieving a ≥30% reduction in long episodes and 72.0% achieving a ≥50% reduction in clinical seizures. RAP-219 was generally well-tolerated, with no serious adverse events reported. These results support advancing RAP-219 into Phase 3 trials, highlighting its potential as a significant treatment option for patients with drug-resistant focal seizures.
The most recent analyst rating on (RAPP) stock is a Buy with a $42.00 price target. To see the full list of analyst forecasts on Rapport Therapeutics, Inc. stock, see the RAPP Stock Forecast page.
Spark’s Take on RAPP Stock
According to Spark, TipRanks’ AI Analyst, RAPP is a Neutral.
Rapport Therapeutics, Inc. faces significant challenges with no revenue and substantial operational losses despite strong equity financing and low leverage. Technical indicators point to a downward trend, and valuation is difficult to ascertain. Positive clinical trial results offer some optimism, but leadership changes contribute to uncertainty.
To see Spark’s full report on RAPP stock, click here.
More about Rapport Therapeutics, Inc.
Rapport Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing small molecule precision medicines for neurological and psychiatric disorders.
Average Trading Volume: 179,032
Technical Sentiment Signal: Buy
Current Market Cap: $524.1M
For a thorough assessment of RAPP stock, go to TipRanks’ Stock Analysis page.